Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

Inclusion Criteria: * Subject is healthy, as determined by medical history. * Subject is between the ages of 15 and 23 years (not yet 24 years). * For subjects who participated in Study MTA02, subject previously received one dose of Menactra® vaccine or Menomune®-A/C/Y/W-135 vaccine. * Did not participate in Study MTA19 (a subset of subjects from Study MTA02 who had been recruited for a follow-up challenge study) * Subject or parent/legal guardian has signed an Institutional Review Board (IRB)-approved informed consent form and subject has signed an IRB-approved assent form. * Before recruitment for the second part of the study, subjects should be thoroughly screened to ensure that they are able to comply with protocol specifications * A negative urine pregnancy test is required for menstruating female subjects. Exclusion Criteria: * History of documented invasive meningococcal disease. * Received any other meningococcal vaccine * Received any vaccine (other than desensitization therapy for allergies) in the 28-day period prior to enrollment * Scheduled to receive any vaccination in the 28-day period after enrollment * Received systemic antibiotic therapy within the 72 hours prior to collection of a blood sample * Actively enrolled or scheduled to be enrolled in another clinical study * Serious chronic disease (i.e., cardiac, renal, neurologic, rheumatologic, metabolic, gastrointestinal, hematologic, psychiatric, or other organ system) * Known or suspected impairment of immunologic function * Acute medical illness with or without fever within 72 hours or an oral temperature ≥ 100.4°F (≥ 38.0°C) at the time of inclusion * Administration of immune globulin, other blood products, or corticosteroid within 3 months of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting \< 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment. * Personal or family history of Guillain-Barre Syndrome * Suspected or known hypersensitivity to any of the vaccine components * Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures * Any condition, which in the opinion of the investigator would pose a health risk to the participant.